新的Claudin18.2-针对胃肠道瘤的向治疗方法
Wei Ye1,2, Mengting Xu1, Yijie Gu2
1Department of Biopharmaceutics, Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.
克劳丁18.2 (CLDN18.2) 是胃肠道 (GI) 瘤的一个有前途的标. 准CLDN18.2为肠胃癌提供了新的精确疗法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 胃肠病学 胃肠病学
背景情况:
- 胃肠道 (GI) 瘤由于其高发病率和死亡率而构成重大和日益增长的健康挑战.
- 迫切需要新的治疗目标来改善肠道恶性瘤的治疗结果.
研究的目的:
- 研究粘附蛋白claudin18.2 (CLDN18.2) 作为GI瘤中潜在的治疗点的作用.
- 探索CLDN18.2作为肠道瘤学准确医学生物标志物的潜力.
主要方法:
- 审查目前关于CLDN18.2表达和功能在胃肠道瘤的研究.
- 对受CLDN18.2.2.影响的信号通路 (PI3K-AKT,RAF-MAPK) 的分析.
- 评估新兴的CLDN18.2向疗法,包括组合疗法,纳米粒子输送和CAR-T细胞疗法.
主要成果:
- 在胃肠道癌症中,CLDN18.2在促进瘤细胞增殖和免疫逃避方面发挥着至关重要的作用.
- CLDN18.2 影响瘤微环境,并与关键的瘤信号通路有关.
- 针对CLDN18.2的治疗方法的进展显示出新的治疗策略的前景.
结论:
- CLDN18.2 是一个非常有前途的和独特的目标,用于开发针对性治疗的胃肠道瘤.
- CLDN18.2的特定表达模式使其成为精确引导治疗干预的有价值生物标志物.
- 对CLDN18.2进行进一步的研究是有必要的,以充分利用其在肠道瘤学中的治疗潜力.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
